Lifitegrast is an integrin antagonist that reduces T-cell-mediated inflammation associated with dry eye disease (DED). This molecule was in pipeline for past few years and several clinical trials have been performed to test its efficacy in treating the signs and symptoms of dry eye syndrome. In July 2016, lifitegrast ophthalmic solution (5%) under the brand name Xiidra by Shire plc was granted an approval from the U.S. Food and Drug Administration (FDA) for treating dry eye syndrome. Xiidra is a twice-daily eye drop solution and only prescription drops indicated for the management of both signs and symptoms of this condition. Shire is expected to launch Xiidra in the United States in the third quarter of 2016. Read More: http://www.transparencymarketresearch.com/lifitegrast-ophthalmic-solution-market.html

1. Lifitegrast Ophthalmic Solution Market -
Global Industry Analysis, Size, Share,
Growth, Trends and Forecast 2016 - 2024
Transparency Market Research Reports incorporated a definite
business overview and investigation inclines on "Lifitegrast
Ophthalmic Solution Market". This report likewise incorporates
more illumination about fundamental review of the business
including definitions, requisitions and worldwide business sector
industry structure.
Dry eye syndrome (DES) also called as dry eye disease (DED)
or keratoconjunctivitis sicca (KCS), is a chronic disease that
leads to lack of tears to maintain sufficient moisture to the eye.
This condition is either a sign of less production of tears or
quick drying of the film of tears. More than 300 million people
are estimated to suffer from this condition. This medical
condition is associated with symptoms such as pain, itching,
redness, blurred vision, light sensitivity, burning and
inflammation.
The key contributing reasons for dry eye syndrome include dry
environment, sun exposure, allergy, smoke exposure, heat or
chemical burns, previous surgery, aging, contact lenses or
infection. Presently, variety of treatment approaches are
available to manage dry eye syndrome such as lubricant

2. treatments, autologous serum eye drops, anti-inflammatory
treatments, and surgery.
Lifitegrast is an integrin antagonist that reduces T-cell-mediated
inflammation associated with dry eye disease (DED). This
molecule was in pipeline for past few years and several clinical
trials have been performed to test its efficacy in treating the
signs and symptoms of dry eye syndrome.
Browse Full Research Report on Lifitegrast Ophthalmic
Solution Market:
http://www.transparencymarketresearch.com/lifitegrast-ophthalmic-
solution-market.html
In July 2016, lifitegrast ophthalmic solution (5%) under the
brand name Xiidra by Shire plc was granted an approval from
the U.S. Food and Drug Administration (FDA) for treating dry
eye syndrome. Xiidra is a twice-daily eye drop solution and only
prescription drops indicated for the management of both signs
and symptoms of this condition. Shire is expected to launch
Xiidra in the United States in the third quarter of 2016.
Being the first U.S. FDA approved product to treat both signs
and symptoms of DES, the market for Xiidra is expected to
grow exponentially in the near future. The key driving factor
attributable to the growing potential of the market is the rising
prevalence of dry eye syndrome worldwide. Increasing demand

3. for advance treatment approaches is set to drive the market
growth for lifitegrast ophthalmic solution.
High incidences of other conditions that can affect the normal
eye functions, such as diabetes, is another underpinning factor
boosting the prevalence of dry eye syndrome. Apart from
diabetes, other conditions that can lead to dry eye syndrome
include vitamin A deficiency, rheumatoid arthritis, lupus, and
thyroid disorders. The growing geriatric population around the
world has also led to an increase in the overall prevalence of dry
eye syndrome.
Earlier, the dry eye syndrome was ignored by patients as the
problems created by the condition were not debilitating.
However, growing amount of awareness about dry eye
syndrome among the people is expected to drive the market
growth exponentially. Additionally, awareness regarding the
management of this condition is assisting the market growth.
The growing problem of pollution is often an underlying factor
for dry eye disease and hence the rising industrialization will
augment the prevalence of the condition. However, the
increasing awareness about the diagnosis and management of
the disease has led to more patient awareness towards the
disease.

4. The market for Xiidra is expected to grow exponentially in the
near future owing to the growth in dry eye syndrome market.
Despite the rising prevalence of dry eye syndrome, the
underdiagnosis of dry eye syndrome is restraining the expected
growth trajectory. Additionally, the trend of self-medication
among the patients remains a major restraint to the market
growth of lifitegrast ophthalmic solution during the forecast
period from 2016 to 2024.
Some of the major companies in the global dry eye syndrome
market are Novartis AG, NicOx SA, Allergan Inc., Bridge
Pharma Inc., Cellzome GmbH, and Santen Pharmaceutical Co.,
Ltd.
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze
information.

5. TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com